Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call indicates strong revenue growth, improved gross margins, and a shift to a self-sustaining business model. Despite some operational challenges in the Products division, the company is expanding its commercial team and launching new services to address market needs. The positive cash flow and strategic focus on growth suggest a positive outlook. However, risks such as customer operational fluctuations and onboarding delays need monitoring. Overall, the market is likely to react positively, with a potential 2% to 8% stock price increase over the next two weeks.

Key Financial Performance

Revenue $24 million in revenue for fiscal year 2025, representing a 30% increase year-over-year compared to 2024. This growth was primarily driven by the expansion in the Pathology Services division and strengthening demand for specialized cancer diagnostic services and molecular testing technologies.

Gross Margin Improved year-over-year from 41% in 2024 to 45% in 2025. This improvement was driven by higher case volumes in the Pathology Services division, a more favorable case mix towards higher-margin tests, and continued improvement of operational efficiency.

Products Division Gross Margin Temporarily impacted by strategic investments, with margins at 30% in Q3 2025. However, in Q4 2025, gross margins leaped to 90% due to a concentrated production run to cover anticipated Q1 2026 demand, illustrating scalability and operational efficiency.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

HemeScreen and Bloodhound molecular platform expansion: Continued expansion of the HemeScreen and Bloodhound molecular platform, including publishing a joint academic study with Memorial Sloan Kettering Cancer Center and presenting a poster at the AMP conference.

New AML testing service: Launching a rapid molecular testing service for acute myeloid leukemia (AML) with next-day results and comprehensive analysis within 5 days.

Increased market engagement: Engaged with over 50 unique investors, family offices, institutional funds, and analysts in 2025, contributing to a 300% share price appreciation.

Products division growth potential: Targeting a $500 million annual addressable market in the U.S. for the Products division over the next 3-5 years.

Revenue growth: Achieved $24 million in revenue for 2025, a 30% year-over-year increase, driven by Pathology Services and specialized cancer diagnostic services.

Improved gross margins: Gross margins improved from 41% in 2024 to 45% in 2025, with the Products division achieving a temporary 90% margin in Q4 due to production planning.

Operational leverage: Incremental revenue absorbed efficiently without proportional increases in operational costs, contributing to improved margins and cash flow.

Shift to growth phase: Transitioned from a cash-using company to a self-sustaining business with positive cash flow, focusing on growth and execution.

Strengthened commercial team: Hired a Chief Commercial Officer and two business development professionals to drive growth in the Products division.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Products Division Revenue Growth: The Products division did not grow as expected in 2025 due to customer operational fluctuations, such as machine downtime and lab tech absences, causing temporary revenue losses. Additionally, the limited commercial team in place hindered growth efforts.

Customer Operational Fluctuations: Operational interruptions at customer facilities, such as machine downtime and staff absences, led to temporary revenue losses and fluctuations in the Products division.

Limited Commercial Team: The company had an insufficient commercial team in 2025, with only one senior executive and one junior sales representative, which limited the ability to drive growth in the Products division.

Onboarding Delays: The onboarding process for new laboratory customers, which includes validation studies, workflow integration, IT, and regulatory reviews, occasionally delayed the start of revenue generation.

Margins in Products Division: Margins in the Products division were temporarily impacted by strategic investments, including facility expansion and additional manufacturing costs, which reduced profitability in Q3 2025.

AML Testing Market Challenges: Most hospital laboratories rely on external reference testing for AML, leading to delays in results delivery. This creates a mismatch between clinical needs and available diagnostic options, posing a challenge for market penetration.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Pathology Services Division Growth: The company aims to continue growing organically while allowing the division to serve as a stable cash-generating foundation. The laboratory infrastructure remains underutilized, enabling efficient absorption of incremental case volume without significant additional costs.

Products Division Expansion: The company plans to focus on accelerating the adoption of HemeScreen and Bloodhound products, converting pipeline laboratories into active revenue-generating customers, and expanding the number of institutions utilizing its platform. A new dedicated and experienced product sales team has been hired to drive this growth.

AML Testing Service Launch: Precipio plans to launch a new service combining rapid molecular testing with next-day results and comprehensive analysis within five days. This service targets unmet needs in acute myeloid leukemia (AML) testing and aims to differentiate the company’s platform.

Revenue Mix Shift: Over the next 3 to 5 years, the company expects its revenue mix to shift from the current 90-10 weighting towards pathology services to a more balanced mix between pathology services and products.

Market Opportunity: The company sees significant opportunities to expand its Products division within an estimated $500 million addressable market annually in the U.S.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Review of Unclear Management Responses

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

PRPO Transcript

Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript

Unknown5-18

The earnings call summary presents a mixed picture: revenue and gross margin improvements are positive, but the net loss and negative cash flow remain concerns. The lack of discussion on strategic initiatives and shareholder returns, along with significant risks highlighted, adds uncertainty. The absence of additional insights from the Q&A section further supports a neutral sentiment, suggesting limited immediate impact on the stock price.

Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript

Positive4-2

Precipio, Inc. (PRPO) Q3 2025 Earnings Call Prepared Remarks Transcript

Positive11-17

The earnings call reveals strong financial performance with significant revenue growth in both divisions, improved gross margins, and positive adjusted EBITDA. The company is financially independent with no need for external capital and has strategic growth plans. Despite temporary margin decline in the Products division due to strategic investments, the overall outlook is optimistic. The market has responded positively, as evidenced by the tripling of the share price. Hence, a positive stock price movement is expected over the next two weeks.

Precipio, Inc. (PRPO) Q2 2025 Earnings Call Transcript

Positive8-14

The earnings call highlights strong financial performance, including significant revenue growth and improved gross margins. Despite some risks, such as customer disruptions and distributor challenges, the company is optimistic about continued growth and breakeven achievement in 2025. The positive outlook on revenue growth, particularly in the Pathology Services and Products divisions, suggests a positive stock price reaction over the next two weeks.

PRPO Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.